Why the decade after menopause is when women's cardiac risk catches up to men's. The timing hypothesis for hormone therapy. The TRAVERSE trial's findings on TRT safety. What anabolic steroids do to the heart. The complete hormone-cardiac framework.
Before menopause, women have significantly lower rates of heart attack and coronary artery disease than men. After menopause, that protection disappears — within a decade, event rates are comparable. The mechanism is the loss of estrogen's direct cardioprotective effects on the vascular wall, lipid metabolism, blood pressure, and inflammation.
This guide explains the science behind the hormone-cardiac relationship for both men and women, the current evidence on when hormone therapy is appropriate, and the TRT safety question answered by the largest randomized trial on the topic.
Six direct cardioprotective mechanisms of estrogen — what the pre-menopausal heart has that post-menopausal arteries lose.
LDL, visceral fat, blood pressure, inflammation, vascular stiffness — the 6 metabolic changes and their cardiovascular timeline.
Why the WHI trial enrolled the wrong age group and what reanalysis revealed about the window of benefit for MHT.
Patch/gel estrogen carries lower DVT and stroke risk than oral estrogen — the clinically relevant delivery route difference.
The 2023 RCT that provided the clearest answer yet on TRT and cardiovascular safety — including the important AFib and DVT signals.
Why supraphysiologic testosterone causes LVH, cardiomyopathy, and sudden death — and why this is distinct from therapeutic TRT.
“Sex hormones are not vanity — they are cardiovascular physiology. The decade following menopause is when women catch up to men in cardiac risk. Understanding why, and using every evidence-based tool appropriately, is some of the most important preventive work we do together.”
The guide that connects sex hormone physiology to cardiovascular prevention.
Get Hormones Guide — $37